



(86) **Date de dépôt PCT/PCT Filing Date:** 2012/06/20
(87) **Date publication PCT/PCT Publication Date:** 2012/12/27
(45) **Date de délivrance/Issue Date:** 2018/02/13
(85) **Entrée phase nationale/National Entry:** 2014/01/28
(86) **N° demande PCT/PCT Application No.:** US 2012/043255
(87) **N° publication PCT/PCT Publication No.:** 2012/177701
(30) **Priorité/Priority:** 2011/06/20 (US61/498,950)


(51) **Cl.Int./Int.Cl.** **A61K 51/04** (2006.01),
A61K 49/00 (2006.01), **C07H 13/02** (2006.01)

(72) **Inventeurs/Inventors:**
TWOROWSKA, IZABELA, US;
SIMS-MOURTADA, JENNIFER, US;
DELPASSAND, EBRAHIM S., US

(73) **Propriétaire/Owner:**
RADIOMEDIX INC., US

(74) **Agent:** NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) **Titre :** COMPOSITIONS, PROCEDES DE SYNTHÈSE ET UTILISATION D'AGENTS CIBLES SUR LES GLUCIDES
(54) **Title:** COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS



(57) **Abrégé/Abstract:**


The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R_1' , R_2' are each independently -OH or -O-alkyl; R_1



(57) Abrégé(suite)/Abstract(continued):

is a hydrogen, a linker, or a ligand; R_3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

WIPO | PCT



(10) International Publication Number

WO 2012/177701 A3

(43) International Publication Date
27 December 2012 (27.12.2012)

(51) International Patent Classification:

C07H 19/056 (2006.01) A61K 49/06 (2006.01)
C07H 19/04 (2006.01)

(21) International Application Number:

PCT/US2012/043255

(22) International Filing Date:

20 June 2012 (20.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/498,950 20 June 2011 (20.06.2011) US

(71) Applicant (for all designated States except US): **RADIOMEDIX INC.** [US/US]; Molecular Research and Discovery, 9701 Richmond Avenue, Suite 222, Houston, TX 77042 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TWOROWSKA, Izabela** [PL/US]; Radiomedix Inc., 9701 Richmond Avenue, Suite 222, Houston, TX 77042 (US). **SIMS-MOURTADA, Jennifer** [US/US]; Radiomedix Inc., 9701 Rich-mond Avenue, Suite 222, Houston, TX 77042 (US). **DEL-PASSAND, Ebrahim, S.** [US/US]; Radiomedix Inc., 9701 Richmond Avenue, Suite 222, Houston, TX 77042 (US).(74) Agents: **LIANG, T., Chyau** et al.; Osha . Liang LLP, 909 Fannin Street, Suite 3500, Houston, TX 77010 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

[Continued on next page]

(54) Title: COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS





FIGURE 1

(57) Abstract: The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R_1' , R_2' are each independently -OH or -O-alkyl; R_1 is a hydrogen, a linker, or a ligand; R_3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.

WO 2012/177701 A3



MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
10 May 2013

Published:

— *with international search report (Art. 21(3))*

COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS

TECHNICAL FIELD

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy, drug development and chemical synthesis. More particularly, it relates to a strategy for synthesis and radiolabeling of targeted ligands.

BACKGROUND OF THE INVENTION

Increased glycolysis is a biochemical hallmark of neoplastic cells (Warburg, 1956). Overexpression of glucose transporters in the cell-membranes of cancer cells results in increased glucose uptake (Kim and Dang, 2006). Furthermore, increased activity of glycolytic enzymes, such as hexokinase, phosphorylates glucose to prohibit its exit from the cell (Parry and Pedersen, 1983). This results in increased accumulation and consumption of glucose by cancer cells. Two families of glucose transporters have been reported in humans: GLUT [Solute Carrier family 2 (facilitated glucose transporter), gene name SLC2A] and SGLT [Solute carrier family 5 (sodium/glucose cotransporter); gene name: SLC5A]. While members of the GLUT family of transporters rely on existing concentration gradients to transport glucose from one side of the membrane to the other, members of the SGLT family transport sugars inside the cell against a concentration gradient by active transport. To date, 14 members of the GLUT family have been identified (GLUT1-14) (Thorens and Mueckler). Although there is significant sequence homology among the GLUTs, they display differential expression in tissues and have varying affinities for glucose and related sugars. GLUT1, GLUT2, and GLUT5 have been shown to be overexpressed in cancer. GLUT3 is primarily expressed on neurons, while GLUT4 and GLUT12 are primarily expressed in cardiac and skeletal muscle and their presence in the cell membrane is regulated by insulin. Six members of the SGLT family have been identified (SGLT1-6). Of these, SGLT-1 and SGLT-2 are implicated in transport of sugars. Expression of SGLT-1 in normal tissues is restricted to the small intestine and renal proximal tubes, while SGLT-2 is expressed on the apical membranes of cells in the renal convoluted proximal tubules. SGLT-1 has high affinity and low capacity for glucose transport, while SGLT-2 has lower affinity and higher capacity. (Thorens and Mueckler) Increased expression of both SGLT-1 and SGLT-2 have been reported in primary and metastatic cancers (Helmke et al., 2004, Ishikawa et al., 2001, Weihua et al., 2008)

The increased accumulation of glucose in neoplastic cells has been exploited for development of diagnostic and therapeutic agents. Radiolabeled carbohydrates have been developed for nuclear imaging of cancer. The most successful of these, 2-¹⁸F-fluoro-2-deoxyglucose (FDG) is currently the gold standard for positron emission tomography (PET). Other sugar-based PET agents have also been developed, including ¹⁸F-Fluoroacetyl-D-glucosamine (Fujiwara et al., 1990), ⁶⁸Ga-2-amino-2-deoxyglucose-based 3-hydroxy-4-pyridonato complexes (Green et al., 2005), ⁶⁸Ga-tripodal trissalicylaldehyde complexes functionalized with xylose, glucose or galactose (Gottschaldt, 2009) ¹¹C-methyl-glucoside (US2010/0008856, Bormons et al, 2003). Radiolabeled sugars have also been developed for SPECT imaging including ^{99m}Tc-Glucosamine-dipicolylamine, (US2006/0051291) ^{99m}Tc-tricarboxyl-N-(2'-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose, (US2006/0051291) ^{99m}Tc-Ethylenedithiol-glucosamine (US 2007/0248537), ¹¹¹In-DOTA-glucosamine, (US2006/0142207A1), ^{99m}Tc-DTPA-deoxyglucose (Chen et al., 2007)

Solid phase approach is a robust, efficient and reproducible method of synthesis of library of compounds. It was successfully applied for the synthesis of peptides, nucleotides,

and glycopeptides. In solid phase, synthesized compounds are temporary attached to the insoluble polymer resins, allowing them to be readily separated from coupling agents and by-products during elongation process. After completion of the synthesis, final compound is released from the polymer support with high yield and purity. Application of solid phase approach for the development of imaging or therapeutic agents is still limited. SPPS was used for the synthesis peptidyl imaging agents (U.S. Patent Application Publication No. 2008/0089842). Amino-functionalized chelator was immobilized on the resin and coupled to the C-terminus and/or backbone of the peptide. After cleaving from the resin, amino-chelator-peptide was labeled with lanthanide metals.

Target-specific radiopharmaceuticals consist of a tissue targeting biomolecule attached to a radionuclide. Commonly used cyclotron-produced radionuclides (i.e. ^{11}C , ^{13}N , ^{15}O and ^{18}F) may be covalently linked to targeting molecules. Alternatively, complexes consisting of a targeting ligand, bifunctional chelating agent and a radionuclide, can be used for nuclear imaging and therapy. In this case, the radionuclide, most commonly a radiometal, is stably coordinated by the bifunctional chelating agent (BFCA). Common BFCAs for radiometallic chelation include DTPA, hydrazinonicotinamide (HYNIC), mercaptoacetyltriglycine (MAG3), tetraaza compounds (i.e. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] and macrocyclic derivatives) and ethylenedicysteine (EC). Each BFCA possesses various combinations of electron-donating atoms for metal chelation. For diagnostic radiopharmaceuticals, γ -emitting radiometals such as ^{68}Ga and ^{64}Cu are commonly used for PET, and $^{99\text{m}}\text{Tc}$, ^{111}In and ^{67}Ga are commonly used for SPECT. Additionally, α -emitting (^{225}Ac and ^{213}Bi) and β -emitting (^{90}Y , ^{177}Lu , and $^{186/188}\text{Re}$) radiometals can be used for radionuclide therapy.

Diagnostic imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) provide anatomical information about disease sites. While these modalities are commonly-used for monitoring changes in tumor size, they cannot assess functional changes occurring within cells or tumors. Functional imaging modalities use radiotracers to image, map and measure biological attributes of disease, such as metabolism, proliferation and surface receptor expression. As a result, functional imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have been experiencing explosive growth due to advances in molecular imaging technology. New molecular imaging targets for diagnosis and therapy have been developed to visualize disease states and pathological processes without surgical exploration of the body. In particular, targeted radiopharmaceuticals offer promising capabilities for the non-invasive assessment of the pathophysiology of diseases. Schillaci, O. & Simonetti, G., *Cancer Biother. Radiopharm.* 19: 1-10 (2004); Paulino, et al, *Semin. Nucl. Med.* 33: 238-43 (2003).

In contrast to traditional radiotherapy methods, radionuclide therapy utilizes active targeting for improved tumor specificity and localization of radiation in tumor cells, thereby minimizing the effects on normal tissue. This approach uses high-affinity cell binding ligands to target radioactivity to tissues expressing a particular receptor. Radiolabeled monoclonal antibodies were among the first targeted therapies developed and have shown moderate clinical success, particularly for the treatment of Non-Hodgkin's lymphoma. However, the large size, limited diffusion and slow blood clearance of the tumor-seeking antibodies have limited their clinical utility. To address these concerns, radiolabeled peptides and low/intermediate molecular weight biologically-active proteins have been employed into the design of novel radionuclide therapies (Pnwar et al., 2005). The smaller size of these


molecules confers desirable pharmacokinetic properties that are favorable for therapy, such as higher target-to-background ratios and faster blood clearance.

SUMMARY OF THE INVENTION

Embodiments of the present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy, drug development and chemical synthesis. More particularly, embodiments of the invention relate to a strategy for solid phase synthesis and radiolabeling of ligands. Embodiments of the invention further relate to methods of using those radiolabeled ligands for radionuclide therapy and tissue-specific disease imaging.

Embodiments of the present invention provide methods for the synthesis of DO2S compounds conjugated to targeting ligands by solid phase approach. In preferred embodiments, the targeting ligands are carbohydrates. The DO2S compounds can be conjugated directly to the targeting ligands or through linkers.

A DO2S derivative has the following general structure:




wherein R_1' , R_2' are each a hydroxyl group, and R_1 is a hydrogen, a linker, or a ligand, and R_3 is a linker or a ligand, and n is an integer from 1 to 10, preferably from 1 to 4. The linkers may be amino acids, peptides, amino alcohols, polyethylene glycols, alkanes, alkenes, alkynes, azide aromatic compounds, carbohydrates, carboxylic acids, esters, phosphororganic compounds, sulfonates.


In accordance with embodiments of the invention, the linker may comprise $-(CH_2)_n-X$, wherein X is a hydroxyl, an amino, or a carboxyl group, and n is an integer from 1 to 10, preferably from 1 to 4, and wherein the linker may be optionally substituted (e.g., one or more H on the alkyl chain may be replaced with an alkyl (e.g., C_1 - C_6 alkyl), a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group).

In accordance with embodiments of the invention, the ligand may be selected from the group consisting of a carbohydrate, peptide, protein, antibody, nucleoside, nucleotide, heterocyclic compound, or alcohol. In preferred embodiments, the ligand may be carbohydrates, such as 2-deoxyglucose, 1'-amino-sugar, 2'-amino-sugar, 1'2'-aminosugar, 2'-amino-methylglycoside, etc. In preferred embodiments, the ligand may be a glucose.

In preferred embodiments, the DO2S derivative has the following structure:



Examples of DO2S derivatives may include:



Some embodiments of the invention comprise a metal or a radionuclide chelated to the DO2S derivative. Generally, any α -emitter, β -emitter, γ -emitter, or β/γ -emitter may be used in conjunction with embodiments of the invention. Preferred α -emitters include ^{211}At , ^{212}Bi and ^{223}Ra . Preferred β -emitters include ^{90}Y and ^{225}Ac . Preferred β/γ -emitters include ^{67}Cu , ^{89}Sr , ^{153}Sm , ^{166}Ho , ^{177}Lu , ^{186}Re and ^{188}Re . Preferred γ -emitters include ^{62}Cu , ^{64}Cu , ^{67}Ga , ^{68}Ga , $^{94\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$ and ^{111}In .

In accordance with some embodiments of the invention, the radionuclide may be one selected from ^{45}Ti , ^{59}Fe , ^{60}Cu , ^{61}Cu , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{67}Ga , ^{68}Ga , ^{89}Sr , ^{90}Y , ^{86}Y , $^{94\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$, ^{111}In , ^{149}Pm , ^{153}Gd , ^{153}Sm , ^{166}Ho , ^{177}Lu , ^{186}Re , ^{188}Re , ^{211}At , ^{212}Bi , or ^{225}Ac . In preferred embodiments, the radionuclide is ^{68}Ga or ^{177}Lu .

Some embodiments of the invention provide methods of radiolabeling DO2S –ligand conjugates on solid phase. In preferred embodiments, the radiometal is ^{68}Ga or ^{177}Lu .

In accordance with some embodiments of the invention, paramagnetic substances, such as Gd, Mn, Cu or Fe, may be used – i.e., chelated with DO2S derivatives for use in embodiments of the present invention.

Some embodiments of the invention provide methods for the treatments of medical conditions by administering to subjects compositions comprising DO2S compounds

conjugated to GLUT-1 targeting ligands. The DO2S compounds may be optionally chelated to a metal species

Some embodiments of the invention provide methods for diagnostic imaging performed on cellular level by application of DO2S compound conjugated to GLUT-1 targeting ligands. The DO2S compound may be optionally labeled with fluorescent, near-infrared imaging probe.

Some embodiments of the invention provide methods for intra-operative diagnosis and treatment of medical conditions by administering to subjects compositions comprising DO2S compounds conjugated to GLUT-1 targeting ligands. The DO2S compound may be optionally labeled with near-infrared imaging probe.

Some embodiments of the invention provide methods for diagnostic imaging of medical conditions. A method comprises administering to a subject a composition comprising a DO2S compound conjugated to a carbohydrate targeting ligand. The DO2S compound may be chelated to a radiometal species.

Some embodiments of the present invention relate to kits for the treatments or diagnosis of a subject. A kit of the invention may comprise a composition comprising a DO2S compound conjugated to a carbohydrate. The DO2S compound may be optionally chelated to a metal species.

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 illustrates the structure of compound 1a

Fig. 2 illustrates the ESI spectra of the t-Bu ester protected compound 1a before the final deprotection (a) and after final deprotection (b). Compound was analyzed using electrospray ionization mass spectroscopy (ESI) in the presence of MeOH: 0.2% of formic acid. The ESI spectra showed mass peak corresponding to compound $m/z=566.2$ (calculated $MW+H=565.37$). The $m/z=734.45$ corresponds to compound 1a before the deprotection.

Fig. 3 illustrates radio-TLC of compound 1a. Retention factor for radiolabeled Glucomedix and $^{68}\text{GaCl}_3$ were 0.9 and 0.1, respectively. Radio-TLC (Bioscan) analysis showed the radiochemical purity of tracer was $> 97\%$.

Fig. 4 illustrates results of cellular uptake study of ^{68}Ga -labeled compound 1a.

Fig. 5 illustrates results of cellular uptake study of ^{177}Lu -labeled compound 1a.

Fig. 6 illustrates the structure of compound 1b.

Fig. 7 illustrates a method of synthesis for compound 1b.

Fig. 8 illustrates the ESI-MS spectra of compound 1b. $m/z= 593.62$ for $[M+H]$ and calculated for $\text{C}_{24}\text{H}_{43}\text{N}_5\text{O}_{12}$ $[M+1]=595.5$

Fig. 9 illustrates the radio-TLC of compound 1b.

Fig. 10 illustrates the structure of compound 2a

Fig. 11 illustrates the ESI-MS spectra of compound 2a before (a) and after purification (b) shown below $m/z= 727.33$ for $[M+H]$ and calculated for $\text{C}_{28}\text{H}_{50}\text{N}_6\text{O}_{16}$ $[M]=726.73$;

Fig. 12 illustrates the radio-TLC of compound 2a

Fig. 13 illustrates the cellular accumulation of ^{68}Ga -2a.

- Fig. 14 illustrates the cellular accumulation and blocking of ^{68}Ga -2a
- Fig. 15 shows blocking of accumulation of ^{68}Ga -2a by glucose transporter inhibitors
- Fig. 16 illustrates the results of cellular uptake and blocking study of ^{177}Lu -2a.
- Fig. 17 illustrates the structure of compound 3
- Fig. 18 illustrates methods of synthesis of compound 3
- Fig. 19 illustrates loading efficiency
- Fig. 20 illustrates the radio-TLC of compound 3
- Fig. 21 illustrates the results of cellular accumulation of ^{68}Ga -3.
- Fig. 22 illustrates the structure of compound 4
- Fig. 23 illustrates of a method of synthesis of compound 4
- Fig. 24 illustrates the ESI-MS spectra of compound 4, $m/z = 720.73$ for $[\text{M}+\text{H}]$ and calculated for compound 4 $m/z = 719.2$
- Fig. 25 illustrates the radio-TLC of compound 4
- Fig. 26 illustrates cellular accumulation of ^{68}Ga -4
- Fig. 27 illustrates cellular accumulation of ^{177}Lu -4
- Fig. 28. Illustrates results of biodistribution study of ^{177}Lu -4
- Fig. 29 illustrates general approach to the synthesis of DO2S-linker-carbohydrates.
- Fig. 30 illustrates an example of a method used for the synthesis of carbohydrate-DO2S-linker-carbohydrate by SPPS.
- Fig. 31. illustrates an example of method used for the synthesis of di-substituted DO2S-[carbohydrate]₂ by SPPS .
- Fig. 32. illustrates structure of compound 5 and predicted physicochemical properties
- Fig. 33. illustrates the ESI-MS spectra of the t-Bu ester protected compound 5 purified by HPLC (C18 column)
- Fig. 34. illustrates the ESI-MS spectra of the t-Bu ester protected compound 5 after purification (precipitation with Et₂O) and collecting of supernatant.
- Fig. 35. illustrates the ESI-MS spectra of the t-Bu ester protected compound 5 after purification (precipitation with Et₂O) and collecting of pellet.
- Fig. 36. illustrates radio-HPLC chromatogram (UV/Vis detection: 220 nm 275 nm) of the deprotected compound 5.
- Fig. 37. illustrates cellular accumulation of ^{68}Ga -5 in SKBr3 breast cancer cell line and results of blocking studies using cold GLUT-1 competitors (genistein, scutellarin, cytochalasin B).
- Fig. 38. illustrates concentration dependent accumulation studies of ^{68}Ga -5 in SKBr3 breast cancer cell line.
- Fig. 39. illustrates an example of method used for the synthesis of DO2S-linker-[carbohydrate]-genistein – compound 6
- Fig. 40. illustrates an example of method used for the synthesis of DO2S-linker-[carbohydrate]-compound 7a,b.

Fig. 41.illustrates structure of compound 7a

Fig. 42.illustrates the ESI-MS spectra of the compound7a.

Fig. 43.illustrates structure of compound 7b

Fig. 44.illustrates the ESI-MS spectra of the compound7b.

Fig. 45. illustrates radio-HPLC chromatogram of compound 7b.

Fig. 46.illustrates cellular accumulation of ^{68}Ga -7b in SKBr3 breast cancer cell line. Specificity of binding was confirmed in blocking studies using cold GLUT-1 competitors (glucose, cytochalasin B).

Fig. 47.illustrates cellular accumulation of ^{68}Ga -7b, ^{68}Ga -1 and ^{68}Ga -copper catalyzed glucosamine conjugate in SKBr3 breast cancer cell line.

DETAILED DESCRIPTION

Embodiments of the invention relate to chelator-based carbohydrate derivatives and method of their synthesis. Chelator-carbohydrate (DO2S-carbohydrate) maybe synthesized from the amino-sugar is directly conjugated to DO2S compound, or it can be coupled to DO2S through any type of the linker (DO2S-linker-carbohydrate).

In accordance with some embodiments of the invention, synthesis of DO2S-carbohydrate can be performed manually on solid phase and using automated instrument, such as a peptide synthesizer.

Resins used for the solid phase synthesis maybe selected from the group consisting of chloro- and bromofunctionalized (Merrifield, 4-bromomethylphenoxy)methyl polystyrene, 2-(4-bromomethylphenoxy)ethyl polystyrene, trityl, 2-chlorotrityl chloride, NOVASYN™ TGT alcohol, NOVASYN™ TGT bromo), amino- and hydrazine functionalized (AM polystyrene and N-methyl aminomethyl polystyrene, NOVASYN™ TG amino, MBHA polystyrene, Rink Amide, Siber, amino trityl, sulfamyl-based, Weinreb AM, Fmoc-4-hydrazinobenzoyl, NOVAGel, alkylaminomethyl-indole, hydroxylamine Wang), hydroxyl functionalized (NovSyn hydroxyl, hydroxymethyl-phenyl, oxime), carboxy, aldehyde (benzyloxybenzaldehyde, FMPB AM, FMPB NOVAGel™, NOVAPEG™ FMBP, FMPE, DFPE, 3-formylindoyl)acetamidomethyl polystyrene -FLA AM resin), enol functionalized (DHP HM resins), thiol functionalized (mercaptomethyl, 3-[4-tritylmercapto)phenylpropionyl AM resins), carbonate functionalized, alkenylcarbonyl functionalized.

Linkers used for the solid phase synthesis of maybe selected from the group of amino acids, peptides, amino alcohols, polyethylene glycols, alkanes, alkenes, alkynes, azide aromatic compounds, carbohydrates, carboxylic acids, esters, fosfororganic compounds, sulfonates.

A targeting ligand may be selected from the group consisting of a carbohydrate, peptide, protein, antibody, nucleoside, nucleotide, heterocyclic compound, or alcohol.

Preferred targeting ligands include carbohydrates, such as 2-deoxyglucose, 1' amino-sugar, 2' amino-sugar, 1'2'-aminosugar, 2'-amino-methylglycoside etc.

The radiometal may be a transition metal ion or lanthanide series element. For example, it may be ^{45}Ti , ^{59}Fe , ^{60}Cu , ^{61}Cu , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{67}Ga , ^{68}Ga , ^{89}Sr , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{153}Gd , ^{153}Sm , ^{166}Ho , ^{186}Re , ^{177}Lu , ^{188}Re , ^{211}At , ^{212}Bi , ^{225}Ac .

Generally, it is believed that virtually any α -emitter, β -emitter, γ -emitter, or β/γ -emitter can be used in conjunction with embodiments of the invention. Preferred α -emitters include ^{211}At , ^{212}Bi and ^{223}Ra . Preferred β -emitters include ^{90}Y and ^{225}Ac . Preferred β/γ -emitters include ^{67}Cu , ^{89}Sr , ^{153}Sm , ^{166}Ho , ^{177}Lu , ^{186}Re and ^{188}Re . Preferred γ -emitters include ^{62}Cu , ^{64}Cu , ^{67}Ga , ^{68}Ga , $^{94\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$ and ^{111}In . It is also envisioned that paramagnetic substances, such as Gd, Mn, Cu or Fe can be chelated with DO2S derivatives for use in conjunction with embodiments of the present invention.

Embodiments of the present invention provide compositions for tissue specific disease imaging and radiotherapy. The disease may be cardiovascular disease, infection, diabetes, or cancer. In a preferred embodiment, the disease is cancer. The cancer may be a solid tumor. In other specific embodiments, the tumor derives, either primarily or as a metastatic form, from cancers such as of the liver, prostate, pancreas, head and neck, breast, brain, colon, adenoid, oral, skin, lung, testes, ovaries, cervix, endometrium, bladder, stomach, and epithelium.

Embodiments of the invention also provide kits for preparing a radiopharmaceutical preparation. The kit generally includes a sealed vial or bag, or any other kind of appropriate container, containing a predetermined quantity of DO2S-carbohydrate conjugate. The components of the kit may be in any appropriate form, such as in liquid, frozen or dry form. In preferred embodiments, the kit components may be provided in lyophilized form. The kit may also include an antioxidant and/or a scavenger. The antioxidant may be any known antioxidant but is preferably vitamin C. Scavengers may be DTPA, EDTA or DOTA.

EXAMPLES

The following examples are provided to illustrate various aspects of the invention, and are not to be construed as limiting the scope of the invention in any manner.

Example 1

A. Synthesis of 1-N-[1,4,7,10-Tetraazacyclododecane-4,7,10-tetra(acetyl)]-2-amino-2-deoxyglucopyranoside (compound 1a)

A.1. Direct coupling of glucosamine hydrochloride to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-*N*-hydroxysuccinimide ester (DOTA-NHS)

Sodium methanolate (3eq.) in methanol was added to glucosamine hydrochloride (1eq. Sigma Aldrich) and stirred for 30 min at room temperature. Solvent was evaporated and free glucosamine was added to a solution of DOTA-NHS (1 eq., Macrocyclics) in ddH₂O in phosphate buffer pH=7. Reaction was stirred at room temperature for 48h, followed by evaporation of solvent under high vacuum. Product was purified by dialysis using Sep-Pak dialysis filters with MW cut off 500 and precipitated by addition of diethyl ether.

A2. Coupling of 1,3,4,6-tetra-O-acetyl- β -D-glucosamine hydrochloride to DOTA tris-*t*-butyl ester

Step a. Preactivation of DOTA chelating agent

To activate the carboxyl groups, 1,4,7,10-tetraazacyclododecane-1,4,7-tris(*t*-butyl acetate)-10-acetic acid (1eq.) was dissolved in 2mL dimethylformamide(DMF), and then *N*-hydroxybenzotriazole (HOBT) and *O*-Benzotriazole-*N,N,N',N'*-tetramethyl-uronium-

hexafluoro-phosphate (HBTU) coupling agents (4eq. each) were added in the presence of 4eq. of N,N-diisopropylamine (DIPEA). Reaction was left at room temperature for 30min.

Step b. Coupling of glucosamine hydrochloride to activated chelating agent

Glucosamine hydrochloride (4eq) was dissolved in DMF in the presence of DIPEA (4eq) and added to the solution of pre-activated DOTA. Reaction was left stirring for 48h at room temperature and was monitored by TLC (chloroform: methanol 1:10) and visualized using anisidine solution or dichlorofluoresceine. Conjugate was purified by extraction using CH₂Cl₂:H₂O and organic fraction was collected. The tert-butyl ester protecting groups were removed in the presence of 30% TFA:CH₂Cl₂:H₂O:TIS (950:250:250), and the product was dialyzed using Sep Pak in millipore water for 48h at room temperature.

A.3. ⁶⁸Ga-radiolabeling of compound 1a.

Compound 1a (1-100 ug) dissolved in 100ul of ultra pure ddH₂O and 500ul of 0.5M NaOAc buffer (pH=4.4). 0.5-10mCi of ⁶⁸GaCl₃ was added (eluted from the ITG ⁶⁸Ge/⁶⁸Ga generator using 0.05M HCl). The final pH of the reaction was 4.1-4.4. The reaction mixture was heated at 70-75°C for 20min. After cooling to room temperature, the reaction was analyzed by radio-TLC.

A.4. In vitro evaluation of ⁶⁸Ga- compound 1a.

a) Cellular uptake study of ⁶⁸Ga-compound 1a. A549 cells were plated in 12 well plates at a density of 1.5×10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5microCi ⁶⁸Ga-1a or ⁶⁸Ga DOTA or DMEM media containing 10mM D-glucose (or other GLUT1 inhibitors such as genistein, scutellarin, cytochalasin B) and 0.5 microCi ⁶⁸Ga-1a. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media were then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivities were counted. Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.

b). Cellular uptake study of ¹⁷⁷Lu-compound 1a. LS174T cells were plated in 12 well plates at a density of 1.5×10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media were removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5microCi ¹⁷⁷Lu-1a or ¹⁷⁷Lu-DOTA or DMEM media containing 10mM D-glucose and 0.5 microCi ¹⁷⁷Lu-1a. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media were then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivities were counted. Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.

Example 2

B.1. Synthesis of N-[1,4,7,10-Tetraazacyclododecane-1,7-bis-(propionic acid)-4,10-bis(acetic acid)]-2-amino-2-deoxyglucopyranoside (compound 1b)

Step.1. Modification of 1,4,7,10-tetraazacyclododecane-1,7-bis(t-butyl acetate)

1,4,7,10-tetraazacyclododecane-1,7-bis(t-butyl acetate), DO2A tBu ester (1eq., Macrocyclics) was dissolved in CH₃CN (5ml) and benzyl 3-bromopropanoate was added in the presence of Et₃N (2.1ml, 12mmol) at temp. 0°C. Reaction was slowly warmed up to room temp. and left stirring for 24h. After evaporation of the solvent under vacuum, product was purified by flash chromatography using 60N silica gel. Deprotection of benzyl ester groups was completed by catalytic hydrogenation under high pressure in the presence of Pd/C during 24h.

Step 2. Preactivation and functionalization of *1,4,7,10-tetraazacyclododecane-1,7-bis(t-butyl acetate)-4,10-bis(propionic acid)*

Modified chelating agent was dissolved in DMF (3mL) in the presence DIPEA (3eq) and coupling agent, HBTU (3eq.) was added to the solution. The mixture was left for 20min at r.t. GlcNAc-b-NH₂ (1.3 eq.) was dissolved in DMSO (1 ml). The solution was heated slightly to dissolve the monosaccharide and added to the pre-activated DO2A chelating agent. The mixture was allowed to react at room temp. with constant stirring 12h. After solvent evaporation, product was purified by extraction using CHCl₃:MeOH and flash silica gel 60N column.

Step 3. Removal of *tBu ester protecting groups*

The tert-butyl ester protecting groups were removed in the presence of 30% TFA:CH₂Cl₂:H₂O:TIS (950:250:250).

B.2. ⁶⁸Ga-labeling of compound 1b.

Radiolabeling was performed in 0.5M NaOAc pH=4.4 at 80°C for 20 min. iTLC was developed in standard running buffer (0.5M NH₄OAc: methanol 1:1 v/v). Radio-TLC (Bioscan) analysis showed the radiochemical purity of tracer was > 98%.

Example 3

C.1. Synthesis of N,N-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-(acetyl)]-1,7-di-(2-amino-2-deoxy-β-D-glucopyranoside (compound 2a)

This is a two step synthesis performed by coupling of glucosamine hydrochloride to 4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.

Step a. preactivation of DOTA chelating agent

To activate the carboxyl groups, 1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacid acetic acid (1eq.) was dissolved in 2mL N-methylpyrrolidine (NMP) and HATU coupling agent (4eq.) was added in the presence of 4eq. of N,N-diisopropylamine (DIPEA). Reaction was left at room temperature for 20min.

Step b. coupling of glucosamine hydrochloride to activated chelating agent

Glucosamine hydrochloride (4eq) was dissolved in NMP in the presence of DIPEA (4eq) and added to the solution of pre-activated DOTA. Reaction was left stirring for one day at room temperature and was traced by TLC (chloroform : methanol 1:10) visualized using anisidine solution or dichlorofluoresceine. After concentration of the reaction under high vacuum, product was extracted using CH₂Cl₂:H₂O and aqueous fraction was collected. Final product was precipitated by addition of ether diethyl on ice.

C.2. ⁶⁸Ga-labeling of compound 2a.

Radiolabeling was performed in 0.5M NaOAc pH=4.4 at 65°C for 20 min. iTLC was developed in standard running buffer (0.5M NH₄OAc: methanol 1:1 v/v) and is shown below on Fig.8. . Radio-TLC (Bioscan) analysis showed the radiochemical purity of tracer was > 99%

C.3. Cellular accumulation of ^{68}Ga -2a.

SKBr3 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5-1 μCi 68Ga-2 or 68Ga DOTA. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation.

C.4. Cellular accumulation and blocking of ^{68}Ga -2a.

SKBr3 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma Aldrich) and 0.5-1 μCi 68Ga-2.. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

C.5. Blocking of accumulation of 68Ga-2a by glucose transporter inhibitors.

SKBr3 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma Aldrich) or other GLUT1 inhibitors (genistein, cytochalasin B, scutellarin) and 0.5-1 μCi 68Ga-2.. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

C.6. Cellular uptake and blocking study of ^{177}Lu -2a.

A549 cells were plated in 12 well plates at a density of 1.5×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5microCi ^{177}Lu -1a or ^{177}Lu - DOTA or DMEM media containing 10mg/ml D-

glucose and 0.5 microCi¹⁷⁷Lu-1a. . Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. . Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.

Example 4.

D.1.Synthesis of N-[1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra-(acetic acid)]- 2-amino-2-deoxyglucopyranoside

Step.1 Coupling :

Fmoc-Asn-Glc (0.015 eq.) was immobilized on the 2-chlorotrityl chloride resin (0.01 eq) in the presence of DIPEA (4 eq) in DMF. Reaction is carried out in presence of excess of DIPEA in order to prevent possible hydrolysis of chloro-resin bond and to neutralize HCl, that form during esterification reaction. Reaction is completed with 1-2h at r.t.

Step.2 Capping

After attachment of Fmoc-Asn-Glc, the unmodified chloride resin was deactivated by addition of ethanol or TFE.

Step 3. Loading efficiency (Fmoc titration)

The Fmoc concentration on the resin was determined by addition of 20% piperidine in DMF to the tested resin. The resultant fulvene-piperidine adduct had UV absorption max at 301nm. Free Fmoc amino acid of known concentration was used as a standard. Loading efficiency of the compound 3 on the resin was close to 15% after 1h. Loading increased to 79% when reaction was left for more than 24h. The lower loading of Fmoc-Asn-Glc conjugate relatively to unprotected Asn is probably caused by steric hindrance and close proximity of carboxyl group and Fmoc group. Loading efficiency was also determined using Kaiser test, that measure the content of free amines after Fmoc deprotection.

Step 4. Deprotection-removal of Fmoc-protecting

To Fmoc-Asn-Glc attached to the resin 20% piperidine/DMF was added and left for 30min followed by wash with 1ml of DMF.

Step4. ⁶⁸Ga-labeling on the resin:

Radiolabeling was performed on the compound still attached to the resin. 200uCi of ⁶⁸Ga was added to the suspension of resin in buffer pH=4.4. reaction was mildly heated at 55°C for 10-12 min.

Step 5. Cleavage from resin

Conjugate was released from in acid-mediated in mild conditions by addition of AcOH in DCM:H₂O:TIS at r.t. in 20-25 min. This process can additionally be accelerated in higher temp. The after addition of AcOH to the resin and incubation at room, flow through is collected and pH of the eluate is adjusted to 4.4 by addition of NaOAc buffer.

D.2. Cellular accumulation of ⁶⁸Ga-3.

A549 cells were plated in 12 well plates at a density of 2*10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5 microCi ⁶⁸Ga-3 or ⁶⁸Ga DOTA. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is presented as % cpm cells/cpm media.

D.3. Cellular accumulation of ^{68}Ga -3.

A549 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5 microCi ^{68}Ga -3 or ^{68}Ga DOTA. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is presented as % cpm cells/cpm media.

Example 5.**E.1.Synthesis. N-1-(ϵ -aminocaproyl)- β -N-acetyl-2-deoxyglucopyranosyl N-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-(acetyl acid)]**

Step1. Synthesis of β -N-Acetylglucosaminyllamine (Figure 23, compound 3). 2-Acetamido-2-deoxy-beta-D-glucopyranosyl azide 3,4,6-triacetate was obtained from Aldrich and was converted to amine (2) by using PPh₃ and DCM following the general literature procedure (Carbohydr. Research, 2001, 331, 439). Deacetylation: To a solution of an acetyl protected amine (2) in dry MeOH, 1-2 drops of ~1M methanolic NaOMe solution were added, and the reaction mixture was kept at rt until completion of the transformation (monitored by tlc). Amberlyst 15 (H⁺ form) resin was then added to remove sodium ions, the resin was filtered off, and the solvent removed in vacuo.

Step2. Synthesis of N-(ϵ -aminocaproyl)- β -N-acetylglucosaminyllamine (Figure 23, compound 5). 6-Trifluoroacetamido-hexanoic acid (1 eq.) was dissolved in DMSO (0.6ml). DIEA (6 eq.) and HBTU (1.3 eq.) were added to the solution. The mixture was allowed to pre activate for approximately 10min. In a separate vial GlcNAc-b-NH₂ (1.3 eq) was dissolved in DMSO (1.3ml). The solution was heated slightly to dissolve the monosaccharide. After the solution was cooled to rt, the monosaccharide solution was added to the activated solution. The mixture was allowed to react to rt with constant stirring for 3h. Final product was purified by flash using silica gel 60N.

Step3. Synthesis of N-1-(ϵ -aminocaproyl)- β -N-acetyl-2-deoxyglucopyranosyl N-[1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra-(acetyl acid)] (Figure 23). DOTA conjugate (6,) was dissolved in DMSO(1ml), Et₃N (0.3ml) and coupling agent HATU were added to the solution. The mixture was allowed to preactivate for approx 30min. In a separate vial N(ϵ -aminocaproyl)-N-acetylglucosaminyllamine (5) was dissolved in DMSO and added to the preactivatedDOTA solution. The mixture was allowed to react at rt with constant stirring for 24h. The reaction mixture was then concentrated under reduced pressure and purified by flash chromatography. Deprotection of the ester groups will be performed by addition of TFA (0.5ml)/DCM (0.5ml) to the DOTA ester at 0°C. Then the reaction was stirred for 3h. The solvent was then removed under reduced pressure, precipitated with anhydrous diethyl ether and dried under high vacuum.

E.2. ^{68}Ga -labeling of compound 4 .Radiolabeling was performed in 0.5M NaOAc pH=4.4 at 70°C for 20 min. iTLC was developed in standard running buffer (0.5M NH₄OAc: methanol 1:1 v/v) . Radio-TLC (Bioscan) analysis showed the radiochemical purity of tracer was > 99%.

E.3. Cellular accumulation of 68Ga-4. A549 and SKBr3 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5-1 μ Ci 68Ga-4 or 68Ga DOTA. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Black lines represent linear regression analysis. Studies were preformed in triplicate..

E.4. Cellular accumulation of 177Lu-4. A549 cells were plated in 12 well plates at a density of 2×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 0.5 microCi 177Lu-4 or 177Lu-DOTA. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is presented as % cpm cells/cpm media

E.5. Biodistribution study of 177Lu-4. Tumor xenografts were generated in 6 week old Swiss nu/nu mice using the human lung adenocarcinoma cell line A549. Xenografts were generated by subcutaneous inoculation of 2×10^6 cells per mouse into the right shoulder. Xenografts were allowed to grow for 7 days.. Mice were fasted for 8-12 hours prior to the start of the study. On the day of the study, mice were anesthetized with Isoflurane and a tail vein cannula was inserted. The tracer was delivered via tail vein injection. . Mice were placed on a warming pad or under a warming lamp to maintain body temperature. Mice were sacrificed at the indicated timepoints and organs were removed, weighed and counted. Data is expressed as % injected dose/gram tissue.

Example 6.

F.1. Synthesis of compound 5.

To activate the carboxyl groups, carbohydrate-genistein(1eq., 20ug) was dissolved in 0.5mL dimethylformamide DMF and dimethylsulfoxide DMSO and N-hydroxybenzotriazole (HOBT) and O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) coupling agents (1.5eq. each) were added in the presence of 4eq. of N,N-diisopropylamine (DIPEA). Reaction was left at room temperature for 30min.

Step b. Coupling of DOTA-linker-NH₂ to activated carbohydrate-genistein derivative

Pre-activated carbohydrate-genistein (1.5eq) was dissolved in DMF in the presence of DIPEA (4eq) and added to the solution DOTA-linker-NH₂. Reaction was left stirring for 48h at room temperature and was traced by TLC (chloroform: methanol 1:10) visualized using anisidine solution or dichlorofluoresceine. After completion of reaction, solution was evaporated and purified on HPLC (C18 column). The tert-butyl ester protecting groups were removed in the

presence of 30% TFA:CH₂Cl₂:H₂O:TIS (950:250:250) and product was purified again by HPLC.

Alternatively, protected compound 5 was purified by precipitation using Et₂O and fraction of supernatant was collected. The tert-butyl ester protecting groups were removed in the presence of 30% TFA:CH₂Cl₂:H₂O:TIS (950:250:250) and product was purified again by precipitation with Et₂O.

F.2. ⁶⁸Ga-radiolabeling of compound 5.

Compound 5 (1-10 ug) dissolved in 100ul of 0.5M NaOAc buffer (pH=4.4). 0.5-4mCi of ⁶⁸GaCl₃ was added (eluted from the ITG ⁶⁸Ge/⁶⁸Ga generator using 0.05M HCl). The final pH of the reaction was 4.1-4.4. The reaction mixture was heated at 95C for 20min. After cooling to room temperature reaction was analyzed by radio-TLC.

F.3. In vitro evaluation of ⁶⁸Ga- compound 5.

a) Cellular uptake study of ⁶⁸Ga-compound 7. A549 cells were plated in 12 well plates at a density of 1.5*10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 12uCi of ⁶⁸Ga-5/ml or ⁶⁸Ga DOTA or DMEM media containing 10mM D-glucose and 12uCi/ml of ⁶⁸Ga-5. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.

F.4. Cellular accumulation and blocking of ⁶⁸Ga-5.

SKBr3 cells were plated in 12 well plates at a density of 1.5*10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma alrich) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

F.4. Blocking of accumulation of ⁶⁸Ga-5 by glucose transporter inhibitors. SKBr3 cells were plated in 12 well plates at a density of 1.5*10⁵ cells per well and grown overnight in DMEM containing glucose transporters inhibitors (scutellarin, glucose, genistein, cytochalasin B) and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma alrich) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes.

Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

Example 7

G.1.Synthesis of compound 6.

To activate the carboxyl groups, tris-tBu ester DOTA (1eq., 20ug) was dissolved in 0.5mL dimethylformamide DMF and dimethylsulfoxide DMSO and N-hydroxybenzotriazole (HOBT) and O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) coupling agents (1.5eq. each) were added in the presence of 4eq. of N,N-diisopropylamine (DIPEA). Reaction was left at room temperature for 30min.

Step b. Coupling of linker-genistein to activated DOTA-tris-tBu ester

Pre-activated DOTATris-tBu ester (1.5eq) was dissolved in DMF in the presence of DIPEA (4eq) and combined with solution of genistein-linker-NH₂. Reaction was left stirring for 48h at room temperature and was traced by TLC (chloroform: methanol 1:10) visualized using anisidine solution or dichlorofluoresceine. After completion of reaction, solution was evaporated and purified on rHPLC (C18). The tert-butyl ester protecting groups were removed in the presence of 30% TFA:CH₂Cl₂:H₂O:TIS (950:250:250) and product was purified again by HPLC.

G.2. ⁶⁸Ga-radiolabeling of compound 6.

Compound 6 (1-10 ug) dissolved in 100ul of 0.5M NaOAc buffer (pH=4.4). 0.5-4mCi of ⁶⁸GaCl₃ was added (eluted from the ITG ⁶⁸Ge/⁶⁸Ga generator using 0.05M HCl). The final pH of the reaction was 4.1-4.4. The reaction mixture was heated at 95C for 20min. After cooling to room temperature reaction was analyzed by radio-TLC.

G.3. In vitro evaluation of ⁶⁸Ga- compound 6.

a) Cellular uptake study of ⁶⁸Ga-compound 6. A549 cells were plated in 12 well plates at a density of 1.5*10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) containing 12uCi of ⁶⁸Ga-6/ml or ⁶⁸Ga DOTA or DMEM media containing 10mM D-glucose and 12uCi/ml of ⁶⁸Ga-6. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.

G.4 Cellular accumulation and blocking of ⁶⁸Ga-6.

SKBr3 cells were plated in 12 well plates at a density of 1.5*10⁵ cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma alrich) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive

media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

G.5. Blocking of accumulation of ^{68}Ga -6 by glucose transporter inhibitors. SKBr3 cells were plated in 12 well plates at a density of 1.5×10^5 cells per well and grown overnight in DMEM containing glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml DMEM (Cellgro) containing GLUT-1 inhibitors (scutellarin, glucose, genistein, cytochalasin B) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

Example 8

H.1. Synthesis of compound 7.

Step.a. Synthesis of compound 7a.

2-acetamido-N-(ϵ -minocaproyl)-2-deoxy- β -D-glucosylamine (1eq., 30ug) was dissolved in 0.5mL dimethylformamide DMF and dimethylsulfoxide DMF/H₂O and were added to MFCO-NHS dissolved in DMF/H₂O. Reaction was left at room temperature for 24h.

Step b. Synthesis of compound 7b

Compound 7a (1.5eq) and DOTA-linker-N3 (10eq) were dissolved in DMF/H₂O and reaction was left stirring for 48h at room temperature. Progress of reaction was monitored by TLC (chloroform: methanol 1:10) visualized using anisidine solution or dichlorofluoresceine. Final product was purified by rHPLC.

H.2. ^{68}Ga -radiolabeling of compound 7b.

Compound 7b (1-10 ug) dissolved in 100ul of 0.5M NaOAc buffer (pH=4.4). 0.5-4mCi of $^{68}\text{GaCl}_3$ was added (eluted from the ITG $^{68}\text{Ge}/^{68}\text{Ga}$ generator using 0.05M HCl). The final pH of the reaction was 4.1-4.4. The reaction mixture was heated at 95°C for 20min. After cooling to room temperature reaction was analyzed by radio-TLC.

H.3. In vitro evaluation of ^{68}Ga - compound 7b.

a) Cellular uptake study of ^{68}Ga -compound 7b. A549 cells were plated in 12 well plates at a density of 1.5×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 30 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and

replaced with 0.5ml glucose free DMEM (Cellgro) containing 12uCi of ^{68}Ga -7b/ml or ^{68}Ga DOTA or DMEM media containing 10mM D-glucose and 12uCi/ml of ^{68}Ga -7b. Cells were incubated at 37°C, 5% CO₂ for the indicated time. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and radioactivity was counted. Data is expressed as %ID (cpm cells/cpm media*100). Error bars represent Standard deviation.



H.4 Cellular accumulation and blocking of ^{68}Ga -7b.

SKBr3 cells were plated in 12 well plates at a density of 1.5×10^5 cells per well and grown overnight in DMEM containing 5.4mg/ml glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma Alrich) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

H.5. Blocking of accumulation of ^{68}Ga -7b by glucose transporter inhibitors.

SKBr3 cells were plated in 12 well plates at a density of 1.5×10^5 cells per well and grown overnight in DMEM containing glucose and 10%FBS at 37°C, 5% CO₂. Cells were fasted for 20 min prior to the study with glucose free DMEM. At the start of the study, media was removed from each well and replaced with 0.5ml glucose free DMEM (Cellgro) or media that contained 100mg/ml D or L glucose (Sigma alrich) or other GLUT1 inhibitors (genistein, scutellarin, cytochalasin B) and 12uCi/ml of radiolabeled compound. Cells were incubated at 37°C, 5% CO₂ for 1 hour. The radioactive media was then removed and cells were washed twice with 1ml PBS. Cells were then trypsinized and transferred to counting tubes. Radioactivity in cells and media were counted at 511keV using a Perkin Elmer Wizard gamma counter. Cells were then collected and lysed with RIPA buffer (Invitrogen) and protein concentration was determined by Pierce BCA protein assay kit (ThermoFisher). Data is expressed as %ID (cpm cells/cpm media*100)/mg protein. Error bars represent Standard deviation. Data represents the average of four separate studies performed in triplicate.

Molecular Formula	= C ₅₁ H ₇₄ N ₆ O ₁₈
Formula Weight	= 1059.16266
Molar Refractivity	= C(57.83%) H(7.04%) N(7.93%) O(27.19%)
Composition	= 267.62 ± 0.3 cm ³
Molar Volume	= 813.1 ± 3.0 cm ³
Parachor	= 2222.3 ± 6.0 cm ³
Index of Refraction	= 1.572 ± 0.02
Surface Tension	= 55.7 ± 3.0 dyne/cm
Density	= 1.302 ± 0.06 g/cm ³
Dielectric Constant	= Not available
Polarizability	= 106.09 ± 0.5 10 ⁻²⁴ cm ³
Monoisotopic Mass	= 1058.50596 Da
Nominal Mass	= 1058 Da
Average Mass	= 1059.1627 Da

Loading efficiency		
COOH-donor	Time	YIELD (%)
	1h	15
	24h	79
Asparagine (lit.)	20min	78
	1h	21
	24h	57
	12h	70


References:

1. Warburg, On the origin of cancer cells, Science, 123(3191):309-14, 1956 Feb 24.
2. Kim and Dang, Cancer's molecular sweet tooth and the Warburg effect, Cancer Res. 2006 Sep 15; 66 (18):8927-30, 2006.
3. Parry and Pedersen, P.L.,J. Biol. Chem., 258:10904–10912 (1983).

4. Thorens and Mueckler The SLC2 (GLUT) family of membrane transporters, *Mol Aspects Med.* 2013 Apr-Jun;34 (2-3):121-38. doi: 10.1016/j.mam.2012.07.001.
5. Helmke BM, Reisser C, Idzko M, Dyckhoff G, Herold-Mende C. Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. *Oral Oncol.* 2004;40:28–35.
6. Ishikawa et al., SGLT gene expression in primary lung cancers and their metastatic lesions. *Jpn J Cancer Res.*, 2001 Aug;92(8):874-9.
7. Weihua et al., Survival of cancer cells is maintained by EGFR independent of its kinase activity, *Cancer Cell.*, 2008 May;13(5):385-93.
8. Green et al., Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix, *Cochrane Database Syst. Rev.*, 2005 Jul 20; (3):CD002225.
9. Chen et al., Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate cancer Cohort Consortium, *Cancer Epidemiol Biomarkers Prev* 16 (10): 1973-82, 2007.
10. Schillaci, O. & Simonetti, G., Fusion imaging in nuclear medicine--applications of dual-modality systems in oncology, *Cancer Biother. Radiopharm*, 19:1-10 (2004).
11. Paulino, et al, Role of fusion in radio therapy treatment planning, *Semin, Nucl. Med.* 33: 238-43 (2003).
12. Pnwar et al., Prediction of 'aggregation-prone' and 'aggregation-susceptible' regions in proteins associated with neurodegenerative diseases. *Journal of Molecular Biology*, 350 (2) 379-92 (2005).

What is claimed is:


1. A compound comprising a DO2S derivative conjugated to a ligand directly or through a linker and optionally chelated to a metal, wherein the DO2S derivative has the following structure:




wherein R_1' , R_2' are each independently-OH or— O-alkyl; R_1 is a hydrogen, a linker, or a ligand; R_3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety, wherein the GLUT1 targeting moiety is 2-deoxyglucose, a 1'-amino-sugar, a 2'-amino-sugar, a 1'2'-diaminosugar, a 2'-amino-methylglycoside, genistein, or scutellarin.

2. The compound of claim 1, wherein the linker comprises $-(CH_2)_m-X$, wherein X is a hydroxyl, an amino, or a carboxyl group, and m is an integer from 1 to 10, and wherein the linker may be optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group.


3. The compound of claim 1, wherein the DO2S derivative has the following structure:




4. The compound of claim 1, comprising a DO2S derivative conjugated to a ligand directly or through a linker and optionally chelated to a metal, wherein the DO2S derivative has the following structure:



wherein R1', R2' are each independently -OH or -O-alkyl; R1 is a hydrogen, a linker, or a ligand; R3 is a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety, wherein the DO2S derivative is selected from the following:




OR



5. The compound of claim 1, wherein the DO2S derivative further comprises a radiometal.
6. The compound of claim 5, wherein the radiometal is ^{68}Ga or ^{177}Lu .

7. A method for synthesizing the DO2S derivative of claim 1, comprising attaching a compound having the following structure to a solid support, directly or through a linker:



wherein R₁' is -OH and R₂' is -O-alkyl.

8. The method of claim 7, further comprising radiolabeling of the DO2S derivative with a radiometal, wherein the radiometal is ^{68}Ga or ^{177}Lu .





FIGURE 1

a)



b)






FIGURE 2

**FIGURE 3****FIGURE 4**




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9





FIGURE 10

A)



B)





FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18

13/30




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22






Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31

22/30




Figure 32

a) Fraction RT=16min.




FIGURE 33




Figure 34




Figure 35




FIGURE 36






FIGURE 37

**FIGURE 38****Figure 39**




FIGURE 40




FIGURE 41




FIGURE 42




FIGURE 43




FIGURE 44




FIGURE 45




FIGURE 46




FIGURE 47

